id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1688499,8302036a-ef2c-4bb9-bce3-8a027980df1d,2T,MR. THEODORE (TED) JONES,20926,"COQUI RADIOPHARMACEUTICALS, CORP.",2015,second_quarter,PHA,American Medical Isotopes Production Act of 2012 that was contained in the National Defense Authorization Act for Fiscal Year 2013.  Acceleration of production of 99 MO using LEU (Low Enriched Uranium).,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2015-04-30T16:46:06.453000-04:00
1689568,841047b9-c46b-4a4b-8500-dcfa61a3e62c,2T,ANGELA STEWART,401103673,"EISAI, INC",2015,second_quarter,PHA,"DEA scheduling of controlled substances
Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481)","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,1,2015-06-11T16:00:20.950000-04:00
1690015,ec950903-d25c-4842-b331-7073538a2f11,Q2,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2015,second_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,127250,0,0,2015-07-01T10:51:59.033000-04:00
1691489,e7150692-a139-44b1-aec5-cfbacd8252d2,Q2,HANCE SCARBOROUGH,17443,ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS,2015,second_quarter,PHA,"Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-07-08T12:29:50.343000-04:00
1691604,ffca5642-33de-4577-a5dc-0130934dd430,Q2,KATE MOSS,25988,CVS HEALTH,2015,second_quarter,PHA,Issues related to prescription drug abuse and drug supply chain safety.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-07-08T14:17:17.637000-04:00
1691690,32122152-27ca-47ed-8882-c9b6b73190e7,Q2,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2015,second_quarter,PHA,General Pharmacy Issues; specialty drug pricing,"Equal Employment Opportunity Commission (EEOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2015-07-08T15:36:07.090000-04:00
1691787,d4713c88-0bde-4d90-b103-e1691e41c09c,2A,"CONNECT 4 STRATEGIES, LLC",401103720,"OREXO US, INC.",2015,second_quarter,PHA,S2645 & HR2536 Recovery Enhancement for Addiction Treatment Act - Patient Caps,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-08T19:06:11.097000-04:00
1692002,3c1f1fba-f7ad-4527-81db-af7b7e0322f0,Q2,THORSEN FRENCH ADVOCACY LLC,400599826,ASTRAZENECA PHARMACEUTICALS LP,2015,second_quarter,PHA,Issues related to access to pharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-07-09T12:58:51.687000-04:00
1692158,0c08c6f5-210f-49e2-b5f6-180f656515a8,Q2,WAXMAN STRATEGIES,401103693,340B HEALTH,2015,second_quarter,PHA,Laws and regulations affecting the 340B Drug Discount Program,"Health & Human Services, Dept of (HHS)",12500,,0,0,2015-07-09T14:43:30.980000-04:00
1692358,49807e2e-0982-4da7-abd2-d31a06ef7de1,Q2,ACG ADVOCACY,2057,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2015,second_quarter,PHA,"Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues.  
Advocating for coverage of pharmacists services under Medicare Part B.  
Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication.  
Advocating for fair and accurate Medicaid pharmacy reimbursement.  
Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management.
Issues related to pharmacy reimbursement for 21st Century Cures.
Issues regarding TriCare coverage for pharmacies.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-09T17:53:56.627000-04:00
1692460,3664d5c8-e22e-4d54-9c2c-1df3527ee676,Q2,"OMNICARE, INC.",321112,OMNICARE INC,2015,second_quarter,PHA,"Drug Enforcement Administration rule on disposal of controlled substances in long term care facilities;
Reclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs;
Controlled substances policy;
Biosimilars policy;
Hazardous drug handling policy;
FDA drug compounding policy",,,20000,0,0,2015-07-10T09:16:38.803000-04:00
1692597,d0d8e7b5-570b-424e-916b-bfdfe211882b,Q2,VALENTE & ASSOCIATES,45983,"SAV-MOR FRANCHISING, INC.",2015,second_quarter,PHA,Medicare Part D,HOUSE OF REPRESENTATIVES,,,0,0,2015-07-10T11:17:27.037000-04:00
1692650,c2f6a2da-380a-42e2-9ae6-8b96461201d1,Q2,NELSON MULLINS RILEY & SCARBOROUGH,285871,"INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.)",2015,second_quarter,PHA,Any legislation and regulation to the treatment of opioid abuse.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-07-10T11:48:06.790000-04:00
1692716,09d4859c-3508-48c3-9d63-0977bb86f1f3,Q2,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2015,second_quarter,PHA,"H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas.
H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas.
HR 6 21st Century Cures Act. IPC is not supportive of some of the ""pay for"" provisions.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-07-10T12:59:58.017000-04:00
1692754,c151004d-ae6a-4713-985d-840ffb837a53,Q2,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2015,second_quarter,PHA,"Increased appropriations for systems to shorten the time between development of a drug and its release to the public
FDA reform as it relates to drug development and research         
Collaborative research on drug development                                
Human factors research related to neuropharmaceuticals","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)",,86662,0,0,2015-07-10T13:15:35.480000-04:00
1693309,9a33130a-6d63-463d-88e7-a3646b62f863,Q2,THE D MAJOR GROUP,401103162,CVS CAREMARK,2015,second_quarter,PHA,"Issues related to innovation in pharmacy delivery, including health information technology.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-13T00:09:39.470000-04:00
1693407,e923f7b9-52d8-4dde-94d4-95b07f8b08f6,Q2,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2015,second_quarter,PHA,"H.R.6 - 21st Century Cures - Issues related to exclusivity rights of certain prescription medications.

Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. 

Issues related to the treatment of pharmacy benefit managers in federal programs. 

Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. 

Issues related to access and affordability for prescription medications for both government and private sector benefit programs.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-13T11:00:02.040000-04:00
1693413,2f55f1c7-3f62-4cb1-b293-021c6dcb07a3,Q2,"PD FRAZER CONSULTING, INC.",65998,CANADA INTERNATIONAL PHARMACY ASSOCIATION,2015,second_quarter,PHA,Monitor the development of proposed bills about the importation of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-07-13T11:02:07.510000-04:00
1693776,08e5931a-01b5-4369-8f51-e74e19b17936,Q2,NELSON MULLINS RILEY & SCARBOROUGH,285871,CASCADE HEMOPHILIA CONSORTIUM,2015,second_quarter,PHA,Issues related to 340B Drug Pricing Progam,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-07-13T14:55:00.397000-04:00
1693784,728bf530-6ae6-4b58-bc4a-f489c7ee6572,Q2,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2015,second_quarter,PHA,"Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-07-13T14:57:07.177000-04:00
1693792,fed95fb7-02bc-43a3-8206-5fcb7410a5c5,Q2,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T15:14:14.787000-04:00
1693810,f2cd0269-700f-433f-9216-c488321a1cca,Q2,ROCK & ASSOCIATES,33545,DIAMONDBACK DRUGS,2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T15:30:25.540000-04:00
1693837,aaf1d6cf-1dc0-4c43-bcc8-32a97df0c0df,Q2,ROCK & ASSOCIATES,33545,TOWN & COUNTRY COMPOUNDING AND CONSULTING,2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T15:42:38.853000-04:00
1693843,f8b0723d-9a63-4385-b4ae-a26c2b95f56d,Q2,ROCK & ASSOCIATES,33545,US COMPOUNDING,2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T15:48:44.887000-04:00
1693855,03d9485a-7e2f-4dd5-9851-9faa6828a292,Q2,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T15:53:53.013000-04:00
1693863,441a13ac-a166-47c1-ba31-00c4cb4318f7,Q2,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T15:56:57.700000-04:00
1693874,e7a539ab-489b-49d6-825f-ef15a0927764,Q2,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T16:03:06.513000-04:00
1693947,014a1b58-40dc-4315-9099-65a206120724,Q2,MR. GALEN RESER,401055978,PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS),2015,second_quarter,PHA,"Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, ""Restoring Access to Medication Act of 2015,"" H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. ""Fairness to Pet Owners Act of 2015,"" S.1200.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-07-13T16:50:06.033000-04:00
1693950,53c42e80-b24c-4e6d-b737-70b8b1306145,Q2,GARY BUEHLER,401103724,"TEVA PHARMACEUTICALS USA, INC.",2015,second_quarter,PHA,Section 505(b)(2) new drug applications and exclusivity period.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-07-13T16:52:07.160000-04:00
1693989,dee85a42-1c88-4030-afa9-bb8b94501637,Q2,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-07-13T17:18:28.807000-04:00
1694006,b3ac72e8-0e2d-47ae-82e6-bc696e805d67,Q2,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2015,second_quarter,PHA,"H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars.

Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies.

CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. 

Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. 

Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. 

CMS call letter focused on changes in policies regarding mail order and pharmacy networks. 

Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-13T17:27:38.167000-04:00
1694017,8e0e580b-75f2-4db8-bace-275be8b74881,Q2,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2015,second_quarter,PHA,"H.R. 6 - 21st Century Cures Act - Issues related to ensuring that medically needed antibiotics are available to the public, curbing opioid abuse in Medicare Part D and maintaining the integrity of the federal Open Payments program.

S. 1549 - The Care Planning Act - supporting advances in End-of-Life Care throughout the nation.

Support of the inclusion of Advanced Care Planning codes in the CMS Physician Fee Schedule (PFS). 


S. 633 - The Promise for antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public.

Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid.

Advancing provisions to highlight Antibiotic Innovation in the President's FY 2016 budget.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-13T17:41:44.433000-04:00
1694080,d89d4372-76b5-466b-a30e-7dad40a6c9d1,Q2,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,11003,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,2015,second_quarter,PHA,"S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, and H.R. 244, MAC Transparency Act","HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2015-07-14T08:36:39.487000-04:00
1694794,67e765e3-8745-4f8a-8648-a50552a6311e,Q2,BROWN RUDNICK LLP,287895,APOTEX CORPORATION,2015,second_quarter,PHA,Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94),"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-14T14:37:49.993000-04:00
1694822,51bf2334-dcca-4389-addc-a7788261dfb2,Q2,BROWN RUDNICK LLP,287895,HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC,2015,second_quarter,PHA,"Issues relating to Implementation of P.L. 113 - 54 (Drug Quality and Security Act); H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 480, H.R. 1725-relating to Prescription Drug Monitoring Programs; S. 524 & H.R. 953 relating to prescription drug abuse","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-14T14:42:04.417000-04:00
1694924,64457dd9-c5fd-4ec4-903c-f1592963219c,Q2,BROWN RUDNICK LLP,287895,"HOSPIRA, INC.",2015,second_quarter,PHA,Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94),"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-14T14:57:14.323000-04:00
1694935,f35c7d44-1c74-4ff1-9e94-337f36e598db,Q2,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2015,second_quarter,PHA,"Pseudoephedrine

Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number).

Oral Contraceptives - S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections

S. 1532 - Affordability is Access Act.  Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections.

Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",,250000,0,0,2015-07-14T14:57:16.697000-04:00
1694951,17baf227-31eb-4d40-8ee0-3de6661638cd,Q2,BROWN RUDNICK LLP,287895,PRIME THERAPEUTICS,2015,second_quarter,PHA,HR 793 - Ensuring Seniors Access to Local Pharmacies Act,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-14T15:01:26.323000-04:00
1694975,1e01578b-9db5-44d9-ba7d-a45c7801b700,Q2,BROWN RUDNICK LLP,287895,AMNEAL PHARMACEUTICALS,2015,second_quarter,PHA,Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94),"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-07-14T15:07:47.183000-04:00
1694981,29c22a5e-6220-47ab-9489-48cfebbd34e3,Q2,BROWN RUDNICK LLP,287895,"EXELA HOLDINGS, LLC",2015,second_quarter,PHA,Issues relating to ANDA review and approval,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-07-14T15:09:51.700000-04:00
1694997,dd89968a-396f-4574-b84d-20833d349b38,Q2,BROWN RUDNICK LLP,287895,ZYDUS PHARMACEUTICALS USA INC.,2015,second_quarter,PHA,Issues relating to generic drug pricing,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-14T15:12:59.747000-04:00
1695484,593c20f9-1e4c-411a-8fe2-5d6f71b14087,Q2,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,35968,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2015,second_quarter,PHA,Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding.,"Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE",,90000,0,0,2015-07-15T09:29:24.027000-04:00
1695541,e808101c-573c-432f-bc23-182080f3ca8b,Q2,RED+BLUE STRATEGIES,400693064,BLUE CROSS BLUE SHIELD OF MASSACHUSETTS,2015,second_quarter,PHA,"H.R. 6 - 21st Century Cures - Issues related to supporting programs to prevent opioid abuse in the Part D program. 

Issues related to opioid abuse.

Issues related to state-based marketplaces.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-15T10:04:02.030000-04:00
1695733,0a5b29e9-c64a-47b8-b579-a43d9bf6bff2,Q2,"MERCURY PUBLIC AFFAIRS, LLC",70175,KALISPELL REGIONAL HEALTHCARE,2015,second_quarter,PHA,Veteran pharmacy issues and polices,"Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2015-07-15T11:00:39.943000-04:00
1695921,d95adbca-5e3d-4089-bbf3-cf004cb5766d,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2015,second_quarter,PHA,"issues related to the 340B drug discount program; HR 6, 21st Century Cures potential amendment","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-15T11:32:15.807000-04:00
1695934,3f9cc7ac-eb4f-4619-8fe8-c29bd768bb49,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2015,second_quarter,PHA,"HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2015-07-15T11:35:20.463000-04:00
1695941,88c62fd0-447d-4409-8a40-23af07142e05,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2015,second_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program.
HR 1600, Patients Access to Treatment Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",50000,,0,0,2015-07-15T11:36:25.073000-04:00
1695953,c37d8758-9586-45b1-bd9c-b6bbad1f62f2,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2015,second_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2015-07-15T11:38:28.777000-04:00
1695960,01cbecaa-70e4-4cd2-9401-29b3f7cea1ac,Q2,CAPITOL HILL CONSULTING GROUP,72053,ENDO PHARMACEUTICALS,2015,second_quarter,PHA,Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-15T11:38:31.073000-04:00
1696238,55cc1a64-ba3a-462f-b5a0-dc25530dd0c4,Q2,MR. VINCENT A. PANVINI,401008845,PHRMA,2015,second_quarter,PHA,"Trans-Pacific Partnership
Patent Reform","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-07-15T12:48:29.260000-04:00
1696922,3bdb087b-ea66-4ce8-81f5-f72da3f75f8c,Q2,CAPITOL HILL CONSULTING GROUP,72053,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2015,second_quarter,PHA,"Issues related to PL 113-54, The Drug Quality and Security Act
Issues related to agriculture appropriations and defense appropriations. Issues related to S. 1406 - saving access to compound medications for special needs patients act.","Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-15T14:49:02.103000-04:00
1696929,235df27d-9564-4fce-8a2d-35da97e40e9b,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,ROCK & ASSOCIATES,2015,second_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",7500,,0,0,2015-07-15T14:50:04.667000-04:00
1696945,da1a0a3f-8de7-4366-8ecf-8502d30664f1,Q2,CAPITOL HILL CONSULTING GROUP,72053,PURDUE PHARMA LLP,2015,second_quarter,PHA,Controlled Drug Substances Act (21 USC 13),"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-15T14:55:15.383000-04:00
1697000,d95b5879-0f17-4a51-a4c7-9d9d17fee602,Q2,RED+BLUE STRATEGIES,400693064,HOSPIRA,2015,second_quarter,PHA,Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-15T15:03:39.887000-04:00
1697067,3588c434-b712-46ba-a894-c3d4677fff52,Q2,THE MATHIS HARPLE GROUP,322911,PILMA,2015,second_quarter,PHA,Patent Protection; 12 Year Data Exclusivity; HR 9 Innovation Act,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-07-15T15:14:24.387000-04:00
1697108,b25c4b1a-c4c0-4229-a2c8-4a7aa169a2a2,Q2,"CHRISTY ELLERBEE CONSULTING, LLC",401103332,"INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.)",2015,second_quarter,PHA,"Pharmaceutical issues relevant to Indivior, PLC; S. 1455 TREAT Act.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-07-15T15:20:49.887000-04:00
1697420,a5607d4a-068e-406b-8ebd-868ddaf753a6,Q2,FTI GOVERNMENT AFFAIRS,401054971,"PERRIGO, INC.",2015,second_quarter,PHA,"Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, ""Restoring Access to Medication Act of 2015,"" H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. ""Fairness to Pet Owners Act of 2015,"" S.1200.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2015-07-15T16:34:26.770000-04:00
1697605,decc05c8-ba97-481b-88e5-52efc71dad86,Q2,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2015,second_quarter,PHA,"Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy","Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,262000,0,0,2015-07-15T17:28:42.340000-04:00
1697754,75507192-c6ba-42f1-8245-cb00237509f0,Q2,EMPIRE CONSULTING GROUP,400703105,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2015,second_quarter,PHA,"Medicare Prescription Drug Act; HR 9, Innovation Act; HR 2005/S. 1083, Medicare Drug Savings Act; 340B Drug pricing program; 21st Century Cures; S.320, Medical Innovation Act; and Independent Payment Advisory Board (IPAB) repeal.",HOUSE OF REPRESENTATIVES,40000,,0,0,2015-07-15T19:46:18.450000-04:00
1697966,76932127-eb90-4b74-9ba4-535cca6c2d9c,Q2,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",4653,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",2015,second_quarter,PHA,Proposals relating to the regulation of direct to consumer prescription drug advertising,"HOUSE OF REPRESENTATIVES,SENATE",,430000,0,0,2015-07-16T09:27:50.010000-04:00
1697975,d1725bba-82b6-4021-ad69-c982184aa5e2,Q2,"WILLIAMS AND JENSEN, PLLC",41454,FAGRON NORTH AMERICA,2015,second_quarter,PHA,Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-16T09:29:52.450000-04:00
1698091,d59e79c6-d25b-45c2-914d-a023eba1cdc7,Q2,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2015,second_quarter,PHA,"Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483,S. 524, H.R. 953); Counterfeit Drugs;21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228)","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,301000,0,0,2015-07-16T10:12:58.597000-04:00
1698686,c1b2a1ef-5ce4-4188-a878-f16916d8b336,Q2,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2015,second_quarter,PHA,"Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act and electronic drug information. Contact with DEA regarding electronic and prescribing of controlled substances.","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,250000,0,0,2015-07-16T11:48:53.590000-04:00
1698947,1cdd06bf-611b-41d5-8c62-aacf50fb55b6,Q2,"RUBICON ADVISORS, LLC",315091,TEVA PHARMACEUTICALS USA,2015,second_quarter,PHA,21st Century Cures Act,"HOUSE OF REPRESENTATIVES,SENATE",105000,,0,0,2015-07-16T12:50:29.067000-04:00
1698963,48940f4b-9e74-421b-b250-1ea5e0f4c930,Q2,"RUBICON ADVISORS, LLC",315091,OFFICE OF GOVERNOR NATHAN DEAL,2015,second_quarter,PHA,"Pharmaceuticals
HR 707, Restoration of America's Wire Act","HOUSE OF REPRESENTATIVES,SENATE",43750,,0,0,2015-07-16T12:56:38.693000-04:00
1698967,85135abb-aefe-4162-a816-8a36df41e007,Q2,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2015,second_quarter,PHA,Food and Drug Administration - Vaccines,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-07-16T12:58:42.943000-04:00
1698980,2da08d80-cb7a-4ca6-a8ec-50badaa74b4f,Q2,"RUBICON ADVISORS, LLC",315091,STATE MUTUAL INSURANCE COMPANY,2015,second_quarter,PHA,21st Century Cares Act,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-07-16T12:58:46.317000-04:00
1698982,a4c06c8f-cc48-40d6-84e2-01154173a22a,Q2,"RUBICON ADVISORS, LLC",315091,ALLIANCE TO PREVENT THE ABUSE OF MEDICINES,2015,second_quarter,PHA,Prescription drug abuse policy,"HOUSE OF REPRESENTATIVES,SENATE",52500,,0,0,2015-07-16T13:00:47.317000-04:00
1698984,f58b7a9d-7042-43bd-a705-b5c8d5bd2d0e,Q2,"RUBICON ADVISORS, LLC",315091,COLLEGE OF AMERICAN PATHOLOGISTS,2015,second_quarter,PHA,"Physician Payment Rates, Electronic Health Records Incentives program","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-07-16T13:00:51.507000-04:00
1698989,5a680884-3584-41dc-ab03-1b3ac3c14156,Q2,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2015,second_quarter,PHA,"Food and Drug Administration, Generic Drug User Fees","HOUSE OF REPRESENTATIVES,SENATE",36000,,0,0,2015-07-16T13:02:52.833000-04:00
1698995,03a3eca4-c6db-4d79-98c2-517173d8f008,Q2,"RUBICON ADVISORS, LLC",315091,"CIPLA USA, INC.",2015,second_quarter,PHA,"Food and Drug Administration, Generic Drug User Fees","HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2015-07-16T13:03:55.380000-04:00
1699179,1e8e74c7-8942-4656-89d6-f0449fe1fd84,Q2,"MASON CONSULTING, LLC",400660986,NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS,2015,second_quarter,PHA,"Legislation and policies relating to:
H.R. 471/S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act
H.R. 639 - Improving Regulatory Transparency for New Medical Therapies Act
S. 1392 - Safe Prescribing of Controlled Substances Act","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office",23450,,0,0,2015-07-16T13:39:53.887000-04:00
1699240,c8e7047c-22e3-40c2-b288-ff098be2b3e4,Q2,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2015,second_quarter,PHA,S 320 - Medical Innovation Act  - NIH funding,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,60000,0,0,2015-07-16T13:53:26.230000-04:00
1699255,8577f14f-e6af-496e-b254-8b64e46e3ccd,Q2,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,340B HEALTH,2015,second_quarter,PHA,"Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3) funding of the Health Resources and Services Administration (HRSA)under the Labor Health & Human Services & Education appropriations bills.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-07-16T13:55:37.323000-04:00
1699290,1bbc659e-1ce7-4200-ad33-9439813cd62c,Q2,AARP,1694,AARP,2015,second_quarter,PHA,"H.R.6, Discussed the House Energy and Commerce Committee 21st Century Cures Initiative and Senate HELP Committee efforts focused on drug and medical device innovation issues.
Discussed the importance of potential savings to both consumers and the federal government of granting Secretarial negotiating authority to the HHS Secretary under Medicare Part D. (no bill #)
Discussed legislation to address pay-for-delay agreements used by drug manufacturers to block lower cost drugs from entering the market.
Discussed the exclusivity period for biologic drugs. (no bill #)
Discussed biologic drug issues including implementation of the new approval pathway for biosimilar drugs. 
Discussed other prescription drug issues and potential legislation on drug importation and least costly alternative payment for Part B drugs. (no bill #)
Discussed the need for data transparency on prescription drug prices and comparativeness effectiveness research.
S. 1137/Hr.9, Discussed patent reform legislation (S. 1137, the PATENT Act and H.R. 9, Innovation Act) and related provisions on the Patent and Trademark Office inter partes review (IPR) process and proposed exemptions for brand name drug patents.
Discussed pending negotiations on the Trans Pacific Partnership (TPP) trade agreement and intellectual property chapter provisions on pharmaceuticals.","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Federal Transit Administration (FTA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA),White House Office",,1889000,0,0,2015-07-16T14:01:51.060000-04:00
1699352,30e6914b-3d9d-4bd2-b4d6-c589a6aad74b,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2015,second_quarter,PHA,"General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements.  Issues related to ""21st Century Cures"" as well as FDA and NIH modernization. Draft legislation regarding microbeads in over the counter products; Issues related to the over the counter drug monograph process; Dietary Supplement amendment to the NDAA bill and H.R. 6, 21st Century Cures Act.","HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",50000,,0,0,2015-07-16T14:14:29.827000-04:00
1699456,399ddb3a-ec14-4696-a248-08c02c39776b,Q2,JOHNS HOPKINS UNIVERSITY,20664,JOHNS HOPKINS UNIVERSITY,2015,second_quarter,PHA,Pharmaceutical drug price increases; 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,120000,0,0,2015-07-16T14:28:32.657000-04:00
1699691,5adcf695-758b-413c-93da-9717b51597b4,Q2,HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY,72793,HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY,2015,second_quarter,PHA,"21st Century Cures

HR 6 21st Century Cures Act Introduced May 19, 2015 by Fred Upton (R-MI) This bill amends the Public Health Service Act to reauthorize the National Institutes of Health (NIH) through FY2018. The NIH Innovation Fund is established to fund a strategic plan,
early stage investigators, and high-risk, high-reward research. The NIH may require scientific data to be shared if the research is fully funded by the NIH. The NIH and the Food and Drug Administration (FDA) must implement a system that allows further research on
clinical trial data. The Centers for Disease Control and Prevention must expand surveillance of neurological diseases. The Council for 21st Century Cures is established to accelerate the discovery, development, and delivery of innovative cures, treatments, and preventive measures. The Department of Health and Human Services must monitor the use of antibacterial and antifungal drugs and resistance to these drugs","HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2015-07-16T14:55:36.207000-04:00
1700133,0e9ee6bc-8739-45dc-b904-57f3d205f8fd,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2015,second_quarter,PHA,"Importation of prescription drugs (S. 122, H.R. 2228)
Rx Pedigree (PL 113-54)
Prescription Drug Monitoring Programs (S. 480, H.R. 1725) 
Counterfeit Drugs 
Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953)
21st Century Cures (H.R. 6)","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2015-07-16T15:56:53.220000-04:00
1700367,f049a889-2022-43a6-9133-bfa1caf6b5b7,Q2,AMERICAN HEALTH CARE ASSOCIATION,2491,AMERICAN HEALTH CARE ASSOCIATION,2015,second_quarter,PHA,"S. 621: Safe Prescribing Act of 2013 - continued monitoring of hydrocodone changes.

Continued monitoring of Nurse Agent 

Continued monitoring of drug disposal issues

Continued monitoring of action on antipsychotic reduction efforts.

H.R. 3392 Medicare Part D patient Safety & Drug Abuse Prevention Act of 2013","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),SENATE,Veterans Affairs, Dept of (VA)",,960000,0,0,2015-07-16T16:32:10.600000-04:00
1700519,4afedc04-a98f-42f9-ba29-bc439937a722,Q2,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2015,second_quarter,PHA,P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,450000,0,0,2015-07-16T17:07:04.650000-04:00
1700665,b4c5ca4f-5826-4c1e-9a70-0505edb3633f,Q2,"TEVA PHARMACEUTICALS USA, INC.",76695,TEVA PHARMACEUTICALS USA INC,2015,second_quarter,PHA,"Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; ""21st Century Cures"" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)",,980000,0,0,2015-07-16T17:35:58.500000-04:00
1700698,f7fdf4a4-efbc-423c-877d-3ccf6b971168,Q2,FTI GOVERNMENT AFFAIRS,401054971,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2015,second_quarter,PHA,"Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law).","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-16T17:44:25.767000-04:00
1700927,104c71de-8054-49f3-bfc9-e8d75e147308,Q2,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2015,second_quarter,PHA,Monitoring biotech legislation,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-07-16T20:12:34.957000-04:00
1700996,2be467c6-a7e0-400c-9553-a3b74936f90a,Q2,THE INGRAM GROUP LLC,400577737,ELI LILLY AND COMPANY,2015,second_quarter,PHA,General issues related to the biopharmaceutical and pharmaceutical industries.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-07-16T22:16:35.703000-04:00
1701372,85301e90-5f8f-43e1-8706-cba3977a8611,Q2,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2015,second_quarter,PHA,"Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price ""gag clauses""; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting ""any willing pharmacy"" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524 - comments on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",,330000,0,0,2015-07-17T08:44:38.867000-04:00
1701447,60c506a3-e009-4c87-8a17-102e3582d2bf,Q2,"ALKERMES, INC.",400458235,"ALKERMES, INC.",2015,second_quarter,PHA,"Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances.  
HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,1332200,0,0,2015-07-17T09:07:14.383000-04:00
1701948,6303531d-adc5-46a5-b494-60c60610e521,Q2,"BLUESTONE STRATEGIES, LLC",400658980,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2015,second_quarter,PHA,"Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues and HR 6, the 21st Century Cures Act.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-17T10:17:30.557000-04:00
1702037,d6f9a23f-5547-4c8a-b61f-acd2402745b2,Q2,"BLUESTONE STRATEGIES, LLC",400658980,AMERICA'S HEALTH INSURANCE PLANS (AHIP),2015,second_quarter,PHA,Specialty Drug Issues,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-17T10:28:14.247000-04:00
1702099,c5e2fb19-8417-471f-bf4e-3e48302dc32c,Q2,AVENUE SOLUTIONS,72111,RICHIE'S SPECIALTY PHARMACY,2015,second_quarter,PHA,"discussions on compounding issues;
TRICARE coverage of compounded medications prepared from bulk chemicals at Department of Defense, Veterans Affairs and TRICARE",SENATE,60000,,0,0,2015-07-17T10:37:51.310000-04:00
1702157,e22ee034-5531-4396-9e1f-1252286d4086,Q2,SANOFI US SERVICES INC.,56838,SANOFI US SERVICES INC,2015,second_quarter,PHA,General issues related to the 340B Federal Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",,510000,0,0,2015-07-17T10:43:19.263000-04:00
1702475,f87bf16c-157e-4e4f-9d96-4546cb31fbf0,Q2,"THE SIMMONS & RUSSELL GROUP, LLC",401103235,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2015,second_quarter,PHA,"Drug importation and the FAIR Generics legislation; An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025, S.CON.RES.11.",SENATE,60000,,0,0,2015-07-17T11:20:15.767000-04:00
1702638,d750cabc-59c6-4dae-9ad6-526e1428a457,Q2,"AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES",2321,AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES,2015,second_quarter,PHA,"HR 2005, S 1083- Medicare Drug Savings Act
HR 6- 21st Century Cures Act- especially patent lengthening provision","HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),SENATE,Treasury, Dept of,U.S. Trade Representative (USTR),White House Office",,690000,0,0,2015-07-17T11:41:35.833000-04:00
1702677,753d8685-df70-47f8-a5c7-8c04cad15986,Q2,"CAPITOL STRATEGIES GROUP, LLC",400462294,PHRMA (ON BEHALF OF WE WORK FOR HEALTH ),2015,second_quarter,PHA,Medical innovation,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-07-17T11:47:55.380000-04:00
1702978,6a9537c3-768d-4ecf-8dd7-5410a8e33f04,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2015,second_quarter,PHA,"PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation 
H.R. 3204 - The Drug Quality and Security Act, implementation
H.R. 6 - 21st Century Cures


***, no specific bill(s), Import Safety, Prescription Drug User Fee Act renewal, drug development policy, drug shortages, supply chain integrity, patent settlements, user fee sequester relief, Innovation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-07-17T12:28:51.793000-04:00
1703039,208f33c0-5822-4bdb-b65e-0c57cbbfc5da,Q2,APOTEX CORP.,310973,APOTEX CORP.,2015,second_quarter,PHA,"HR 6 - The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals;

FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes;

HR 2841 - The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing;

S 1137 - The FAIR Generics Act, provisions relating to market blockages caused by ""parked"" 180 day exclusivity periods;

Federal policy relating to International Nonproprietary Names for biosimilars;

Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, The Patient Protection and Affordable Care Act; and 

Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, provisions in Title 3, Fees Relating to Generic Drugs.","HOUSE OF REPRESENTATIVES,SENATE",,260000,0,0,2015-07-17T12:44:33.497000-04:00
1703317,a7cdf0c5-2e71-4bf2-b92b-7ec42844da98,Q2,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2015,second_quarter,PHA,"Reimbursement of pharmacist services - HR592/S314
Transitions of care
Risk evaluation and mitigation services
Track and trace/supply chain
Health information technology
Immunizations
Compounding
Tele-medicine
Quality rating
AMP FULs
Biosimiliars
Drug importation
Generics labeling
Preferred pharmacy network - HR793
Electronic labeling
Home infusion - HR605/S275
21st century cures","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,27243,0,0,2015-07-17T13:33:26.517000-04:00
1703459,1038386d-7d4c-4189-86dc-1c238fe4190a,Q2,"THE STRATEGY GROUP, INC.",401103637,PHRMA,2015,second_quarter,PHA,340B Pharmacy Program.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-07-17T13:49:45.287000-04:00
1703777,6e721e25-833f-4eee-81e0-a3c50a35a9e3,2A,SANOFI US SERVICES INC.,56838,SANOFI US SERVICES INC,2015,second_quarter,PHA,General issues related to the 340B Federal Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",,840000,0,0,2015-07-17T14:30:18.917000-04:00
1703821,56a31d4f-59f3-401f-9440-a045dd3c9165,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,PHRMA,2015,second_quarter,PHA,"PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation
H.R. 3204 - The Drug Quality and Security Act, implementation
H.R. 6 - 21st Century Cures

***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act and associated policies, user fee sequester, innovation","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2015-07-17T14:33:45.760000-04:00